Aventis/ViroPharma Picovir To Initially Target “High Risk” Cold Patients
Aventis/ViroPharma's common cold therapy Picovir (pleconaril) will initially be marketed as a treatment for high-risk patients, Aventis Pharma CEO Richard Markham said Feb. 13
Aventis/ViroPharma's common cold therapy Picovir (pleconaril) will initially be marketed as a treatment for high-risk patients, Aventis Pharma CEO Richard Markham said Feb. 13